nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—Hydrocortisone—psoriasis	0.365	1	CrCtD
Drospirenone—NR3C2—Betamethasone—psoriasis	0.0597	0.218	CbGbCtD
Drospirenone—NR3C2—Prednisolone—psoriasis	0.059	0.215	CbGbCtD
Drospirenone—PGR—Betamethasone—psoriasis	0.0386	0.141	CbGbCtD
Drospirenone—NR3C2—Dexamethasone—psoriasis	0.0348	0.127	CbGbCtD
Drospirenone—PGR—Dexamethasone—psoriasis	0.0224	0.082	CbGbCtD
Drospirenone—BCHE—Triamcinolone—psoriasis	0.0211	0.077	CbGbCtD
Drospirenone—Flurandrenolide—Fluocinonide—psoriasis	0.018	0.0575	CrCrCtD
Drospirenone—Flurandrenolide—Fluocinolone Acetonide—psoriasis	0.0175	0.0559	CrCrCtD
Drospirenone—PTGS2—Triamcinolone—psoriasis	0.0162	0.0592	CbGbCtD
Drospirenone—Eplerenone—Hydrocortisone—psoriasis	0.0149	0.0475	CrCrCtD
Drospirenone—PTGS2—Betamethasone—psoriasis	0.0139	0.0508	CbGbCtD
Drospirenone—Formestane—Hydrocortisone—psoriasis	0.0125	0.0397	CrCrCtD
Drospirenone—Spironolactone—Hydrocortisone—psoriasis	0.0113	0.0359	CrCrCtD
Drospirenone—Potassium Canrenoate—Hydrocortisone—psoriasis	0.0113	0.0359	CrCrCtD
Drospirenone—Megestrol acetate—Hydrocortisone—psoriasis	0.0103	0.0329	CrCrCtD
Drospirenone—Potassium Canrenoate—Prednisone—psoriasis	0.00971	0.0309	CrCrCtD
Drospirenone—Medrysone—Hydrocortisone—psoriasis	0.00952	0.0303	CrCrCtD
Drospirenone—Potassium Canrenoate—Prednisolone—psoriasis	0.00948	0.0302	CrCrCtD
Drospirenone—Medroxyprogesterone Acetate—Hydrocortisone—psoriasis	0.00917	0.0292	CrCrCtD
Drospirenone—Flurandrenolide—Hydrocortisone—psoriasis	0.00885	0.0282	CrCrCtD
Drospirenone—Norethindrone—Hydrocortisone—psoriasis	0.00828	0.0264	CrCrCtD
Drospirenone—Flurandrenolide—Betamethasone—psoriasis	0.00822	0.0262	CrCrCtD
Drospirenone—Flurandrenolide—Dexamethasone—psoriasis	0.00822	0.0262	CrCrCtD
Drospirenone—PTGS2—Dexamethasone—psoriasis	0.00809	0.0296	CbGbCtD
Drospirenone—Cortisone acetate—Hydrocortisone—psoriasis	0.00802	0.0256	CrCrCtD
Drospirenone—Medrysone—Prednisolone—psoriasis	0.008	0.0255	CrCrCtD
Drospirenone—Flurandrenolide—Prednisolone—psoriasis	0.00744	0.0237	CrCrCtD
Drospirenone—Testolactone—Betamethasone—psoriasis	0.00723	0.023	CrCrCtD
Drospirenone—Testolactone—Dexamethasone—psoriasis	0.00723	0.023	CrCrCtD
Drospirenone—Testolactone—Triamcinolone—psoriasis	0.00706	0.0225	CrCrCtD
Drospirenone—Progesterone—Hydrocortisone—psoriasis	0.00697	0.0222	CrCrCtD
Drospirenone—Testosterone Propionate—Hydrocortisone—psoriasis	0.00697	0.0222	CrCrCtD
Drospirenone—Cortisone acetate—Prednisone—psoriasis	0.00691	0.022	CrCrCtD
Drospirenone—Methyltestosterone—Hydrocortisone—psoriasis	0.0068	0.0217	CrCrCtD
Drospirenone—Cortisone acetate—Prednisolone—psoriasis	0.00674	0.0215	CrCrCtD
Drospirenone—Testolactone—Prednisone—psoriasis	0.0067	0.0214	CrCrCtD
Drospirenone—Testolactone—Prednisolone—psoriasis	0.00654	0.0209	CrCrCtD
Drospirenone—Testosterone—Hydrocortisone—psoriasis	0.00605	0.0193	CrCrCtD
Drospirenone—Progesterone—Prednisolone—psoriasis	0.00586	0.0187	CrCrCtD
Drospirenone—Methyltestosterone—Prednisone—psoriasis	0.00585	0.0187	CrCrCtD
Drospirenone—Methyltestosterone—Prednisolone—psoriasis	0.00571	0.0182	CrCrCtD
Drospirenone—Hydrocortisone—Betamethasone—psoriasis	0.00528	0.0168	CrCrCtD
Drospirenone—Hydrocortisone—Dexamethasone—psoriasis	0.00528	0.0168	CrCrCtD
Drospirenone—Hydrocortisone—Triamcinolone—psoriasis	0.00516	0.0164	CrCrCtD
Drospirenone—Testosterone—Prednisolone—psoriasis	0.00509	0.0162	CrCrCtD
Drospirenone—Hydrocortisone—Prednisone—psoriasis	0.0049	0.0156	CrCrCtD
Drospirenone—Hydrocortisone—Prednisolone—psoriasis	0.00478	0.0152	CrCrCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—REN—psoriasis	0.0013	0.122	CbGpPWpGaD
Drospirenone—Embolism venous—Acitretin—psoriasis	0.00104	0.0303	CcSEcCtD
Drospirenone—Embolism—Acitretin—psoriasis	0.000815	0.0238	CcSEcCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—ACE—psoriasis	0.000813	0.0762	CbGpPWpGaD
Drospirenone—Uterine haemorrhage—Cyclosporine—psoriasis	0.000796	0.0233	CcSEcCtD
Drospirenone—Breast pain—Acitretin—psoriasis	0.0006	0.0175	CcSEcCtD
Drospirenone—Thromboembolic event—Methotrexate—psoriasis	0.000571	0.0167	CcSEcCtD
Drospirenone—Haemoglobin—Tazarotene—psoriasis	0.000552	0.0161	CcSEcCtD
Drospirenone—Haemorrhage—Tazarotene—psoriasis	0.000549	0.016	CcSEcCtD
Drospirenone—Embolism venous—Prednisolone—psoriasis	0.000502	0.0147	CcSEcCtD
Drospirenone—Embolism venous—Hydrocortisone—psoriasis	0.00049	0.0143	CcSEcCtD
Drospirenone—Thrombosis—Mycophenolic acid—psoriasis	0.000486	0.0142	CcSEcCtD
Drospirenone—Embolism venous—Triamcinolone—psoriasis	0.000461	0.0135	CcSEcCtD
Drospirenone—Embolism venous—Betamethasone—psoriasis	0.000419	0.0122	CcSEcCtD
Drospirenone—Embolism venous—Dexamethasone—psoriasis	0.000419	0.0122	CcSEcCtD
Drospirenone—Embolism—Prednisolone—psoriasis	0.000394	0.0115	CcSEcCtD
Drospirenone—Thrombosis—Cyclosporine—psoriasis	0.000393	0.0115	CcSEcCtD
Drospirenone—Cerebrovascular accident—Acitretin—psoriasis	0.000388	0.0113	CcSEcCtD
Drospirenone—Embolism—Hydrocortisone—psoriasis	0.000385	0.0112	CcSEcCtD
Drospirenone—Thrombosis—Mycophenolate mofetil—psoriasis	0.000384	0.0112	CcSEcCtD
Drospirenone—Migraine—Acitretin—psoriasis	0.000374	0.0109	CcSEcCtD
Drospirenone—Depression—Methoxsalen—psoriasis	0.000368	0.0107	CcSEcCtD
Drospirenone—Embolism venous—Prednisone—psoriasis	0.000365	0.0106	CcSEcCtD
Drospirenone—Embolism—Triamcinolone—psoriasis	0.000363	0.0106	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Clobetasol propionate—psoriasis	0.000343	0.01	CcSEcCtD
Drospirenone—Loss of libido—Methotrexate—psoriasis	0.000333	0.00973	CcSEcCtD
Drospirenone—Embolism—Dexamethasone—psoriasis	0.000329	0.00961	CcSEcCtD
Drospirenone—Embolism—Betamethasone—psoriasis	0.000329	0.00961	CcSEcCtD
Drospirenone—Skin disorder—Clobetasol propionate—psoriasis	0.000321	0.00938	CcSEcCtD
Drospirenone—Breast pain—Cyclosporine—psoriasis	0.000319	0.00931	CcSEcCtD
Drospirenone—Breast pain—Mycophenolate mofetil—psoriasis	0.000311	0.00909	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—psoriasis	0.000309	0.00902	CcSEcCtD
Drospirenone—Haemoglobin—Calcitriol—psoriasis	0.000297	0.00867	CcSEcCtD
Drospirenone—Haemorrhage—Calcitriol—psoriasis	0.000295	0.00862	CcSEcCtD
Drospirenone—Nervous system disorder—Fluocinonide—psoriasis	0.000292	0.00854	CcSEcCtD
Drospirenone—Depression—Acitretin—psoriasis	0.000292	0.00852	CcSEcCtD
Drospirenone—Skin disorder—Fluocinonide—psoriasis	0.00029	0.00846	CcSEcCtD
Drospirenone—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000288	0.157	CbGdCrCtD
Drospirenone—Embolism—Prednisone—psoriasis	0.000287	0.00837	CcSEcCtD
Drospirenone—Erythema multiforme—Calcitriol—psoriasis	0.000279	0.00815	CcSEcCtD
Drospirenone—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000274	0.0257	CbGpPWpGaD
Drospirenone—Breast disorder—Hydroxyurea—psoriasis	0.000269	0.00787	CcSEcCtD
Drospirenone—Haemoglobin—Acitretin—psoriasis	0.000264	0.00771	CcSEcCtD
Drospirenone—Haemorrhage—Acitretin—psoriasis	0.000263	0.00767	CcSEcCtD
Drospirenone—NR3C2—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000262	0.0246	CbGpPWpGaD
Drospirenone—Affect lability—Mycophenolic acid—psoriasis	0.000246	0.00718	CcSEcCtD
Drospirenone—Embolism—Methotrexate—psoriasis	0.00024	0.007	CcSEcCtD
Drospirenone—Angiopathy—Acitretin—psoriasis	0.000238	0.00696	CcSEcCtD
Drospirenone—Mood swings—Mycophenolic acid—psoriasis	0.000237	0.00691	CcSEcCtD
Drospirenone—PGR—Ovarian Infertility Genes—VDR—psoriasis	0.000232	0.0217	CbGpPWpGaD
Drospirenone—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000231	0.126	CbGdCrCtD
Drospirenone—Mental disorder—Fluocinolone Acetonide—psoriasis	0.00023	0.0067	CcSEcCtD
Drospirenone—Skin disorder—Methoxsalen—psoriasis	0.000229	0.00668	CcSEcCtD
Drospirenone—Breast disorder—Mycophenolic acid—psoriasis	0.000226	0.00659	CcSEcCtD
Drospirenone—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000224	0.122	CbGdCrCtD
Drospirenone—Haemoglobin—Hydroxyurea—psoriasis	0.000207	0.00605	CcSEcCtD
Drospirenone—Haemorrhage—Hydroxyurea—psoriasis	0.000206	0.00602	CcSEcCtD
Drospirenone—Skin disorder—Calcitriol—psoriasis	0.000204	0.00595	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Methoxsalen—psoriasis	0.000203	0.00593	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.000202	0.019	CbGpPWpGaD
Drospirenone—PGR—Nuclear Receptors—VDR—psoriasis	0.000202	0.0189	CbGpPWpGaD
Drospirenone—Cerebrovascular accident—Mycophenolate mofetil—psoriasis	0.000201	0.00587	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.0002	0.0188	CbGpPWpGaD
Drospirenone—Affect lability—Cyclosporine—psoriasis	0.000199	0.00581	CcSEcCtD
Drospirenone—Migraine—Cyclosporine—psoriasis	0.000199	0.00581	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000197	0.0185	CbGpPWpGaD
Drospirenone—BCHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—psoriasis	0.000196	0.0183	CbGpPWpGaD
Drospirenone—Affect lability—Mycophenolate mofetil—psoriasis	0.000194	0.00566	CcSEcCtD
Drospirenone—Mood swings—Cyclosporine—psoriasis	0.000191	0.00559	CcSEcCtD
Drospirenone—Angiopathy—Hydroxyurea—psoriasis	0.000187	0.00546	CcSEcCtD
Drospirenone—Mood swings—Mycophenolate mofetil—psoriasis	0.000187	0.00545	CcSEcCtD
Drospirenone—Breast disorder—Cyclosporine—psoriasis	0.000183	0.00533	CcSEcCtD
Drospirenone—NR3C2—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000183	0.0171	CbGpPWpGaD
Drospirenone—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.000183	0.00533	CcSEcCtD
Drospirenone—Skin disorder—Acitretin—psoriasis	0.000181	0.00529	CcSEcCtD
Drospirenone—Affect lability—Prednisolone—psoriasis	0.000181	0.00528	CcSEcCtD
Drospirenone—Nausea—Beclomethasone—psoriasis	0.000179	0.00522	CcSEcCtD
Drospirenone—Affect lability—Hydrocortisone—psoriasis	0.000177	0.00516	CcSEcCtD
Drospirenone—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.000176	0.0165	CbGpPWpGaD
Drospirenone—Mood swings—Prednisolone—psoriasis	0.000174	0.00508	CcSEcCtD
Drospirenone—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000174	0.0948	CbGdCrCtD
Drospirenone—Haemoglobin—Mycophenolic acid—psoriasis	0.000174	0.00507	CcSEcCtD
Drospirenone—Haemorrhage—Mycophenolic acid—psoriasis	0.000173	0.00504	CcSEcCtD
Drospirenone—Mood swings—Hydrocortisone—psoriasis	0.00017	0.00497	CcSEcCtD
Drospirenone—Affect lability—Triamcinolone—psoriasis	0.000166	0.00486	CcSEcCtD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000165	0.0155	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Acitretin—psoriasis	0.000161	0.0047	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000161	0.00469	CcSEcCtD
Drospirenone—Mood swings—Triamcinolone—psoriasis	0.00016	0.00468	CcSEcCtD
Drospirenone—PGR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000159	0.015	CbGpPWpGaD
Drospirenone—Angiopathy—Mycophenolic acid—psoriasis	0.000157	0.00458	CcSEcCtD
Drospirenone—Depression—Cyclosporine—psoriasis	0.000155	0.00453	CcSEcCtD
Drospirenone—AR—Nuclear Receptors—VDR—psoriasis	0.000154	0.0144	CbGpPWpGaD
Drospirenone—Acute coronary syndrome—Cyclosporine—psoriasis	0.000153	0.00448	CcSEcCtD
Drospirenone—Myocardial infarction—Cyclosporine—psoriasis	0.000153	0.00446	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000152	0.00443	CcSEcCtD
Drospirenone—Depression—Mycophenolate mofetil—psoriasis	0.000151	0.00442	CcSEcCtD
Drospirenone—Mental disorder—Mycophenolic acid—psoriasis	0.000151	0.00442	CcSEcCtD
Drospirenone—Affect lability—Dexamethasone—psoriasis	0.000151	0.00441	CcSEcCtD
Drospirenone—Affect lability—Betamethasone—psoriasis	0.000151	0.00441	CcSEcCtD
Drospirenone—Migraine—Dexamethasone—psoriasis	0.000151	0.00441	CcSEcCtD
Drospirenone—Migraine—Betamethasone—psoriasis	0.000151	0.00441	CcSEcCtD
Drospirenone—Acute coronary syndrome—Mycophenolate mofetil—psoriasis	0.00015	0.00437	CcSEcCtD
Drospirenone—Myocardial infarction—Mycophenolate mofetil—psoriasis	0.000149	0.00435	CcSEcCtD
Drospirenone—Mood swings—Dexamethasone—psoriasis	0.000145	0.00424	CcSEcCtD
Drospirenone—Mood swings—Betamethasone—psoriasis	0.000145	0.00424	CcSEcCtD
Drospirenone—Nervous system disorder—Hydroxyurea—psoriasis	0.000144	0.0042	CcSEcCtD
Drospirenone—Skin disorder—Hydroxyurea—psoriasis	0.000142	0.00416	CcSEcCtD
Drospirenone—PGR—Nuclear Receptors—PPARG—psoriasis	0.000141	0.0132	CbGpPWpGaD
Drospirenone—Haemoglobin—Cyclosporine—psoriasis	0.00014	0.0041	CcSEcCtD
Drospirenone—Nausea—Methoxsalen—psoriasis	0.00014	0.00408	CcSEcCtD
Drospirenone—Haemorrhage—Cyclosporine—psoriasis	0.00014	0.00408	CcSEcCtD
Drospirenone—Acute coronary syndrome—Prednisolone—psoriasis	0.00014	0.00408	CcSEcCtD
Drospirenone—BCHE—Peptide hormone metabolism—REN—psoriasis	0.000139	0.0131	CbGpPWpGaD
Drospirenone—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000139	0.076	CbGdCrCtD
Drospirenone—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000139	0.076	CbGdCrCtD
Drospirenone—Myocardial infarction—Prednisolone—psoriasis	0.000139	0.00405	CcSEcCtD
Drospirenone—Haemoglobin—Mycophenolate mofetil—psoriasis	0.000137	0.004	CcSEcCtD
Drospirenone—Acute coronary syndrome—Hydrocortisone—psoriasis	0.000136	0.00398	CcSEcCtD
Drospirenone—Haemorrhage—Mycophenolate mofetil—psoriasis	0.000136	0.00398	CcSEcCtD
Drospirenone—Myocardial infarction—Hydrocortisone—psoriasis	0.000136	0.00396	CcSEcCtD
Drospirenone—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000135	0.0738	CbGdCrCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000133	0.0124	CbGpPWpGaD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000132	0.0123	CbGpPWpGaD
Drospirenone—Affect lability—Prednisone—psoriasis	0.000131	0.00384	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.00013	0.0122	CbGpPWpGaD
Drospirenone—Acute coronary syndrome—Triamcinolone—psoriasis	0.000128	0.00375	CcSEcCtD
Drospirenone—Haemoglobin—Prednisolone—psoriasis	0.000128	0.00373	CcSEcCtD
Drospirenone—Myocardial infarction—Triamcinolone—psoriasis	0.000128	0.00373	CcSEcCtD
Drospirenone—Haemorrhage—Prednisolone—psoriasis	0.000127	0.00371	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000127	0.00371	CcSEcCtD
Drospirenone—Angiopathy—Cyclosporine—psoriasis	0.000127	0.0037	CcSEcCtD
Drospirenone—Mood swings—Prednisone—psoriasis	0.000127	0.00369	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000127	0.00369	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000126	0.0118	CbGpPWpGaD
Drospirenone—Haemoglobin—Hydrocortisone—psoriasis	0.000125	0.00364	CcSEcCtD
Drospirenone—Nausea—Calcitriol—psoriasis	0.000125	0.00364	CcSEcCtD
Drospirenone—Haemorrhage—Hydrocortisone—psoriasis	0.000124	0.00363	CcSEcCtD
Drospirenone—Angiopathy—Mycophenolate mofetil—psoriasis	0.000124	0.00361	CcSEcCtD
Drospirenone—Mental disorder—Cyclosporine—psoriasis	0.000122	0.00357	CcSEcCtD
Drospirenone—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000121	0.0114	CbGpPWpGaD
Drospirenone—Nervous system disorder—Mycophenolic acid—psoriasis	0.00012	0.00351	CcSEcCtD
Drospirenone—Mental disorder—Mycophenolate mofetil—psoriasis	0.000119	0.00349	CcSEcCtD
Drospirenone—Skin disorder—Mycophenolic acid—psoriasis	0.000119	0.00348	CcSEcCtD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000118	0.0111	CbGpPWpGaD
Drospirenone—Haemoglobin—Triamcinolone—psoriasis	0.000118	0.00343	CcSEcCtD
Drospirenone—Haemorrhage—Triamcinolone—psoriasis	0.000117	0.00341	CcSEcCtD
Drospirenone—Acute coronary syndrome—Betamethasone—psoriasis	0.000117	0.0034	CcSEcCtD
Drospirenone—Acute coronary syndrome—Dexamethasone—psoriasis	0.000117	0.0034	CcSEcCtD
Drospirenone—NR3C2—Gene Expression—TARS—psoriasis	0.000116	0.0109	CbGpPWpGaD
Drospirenone—Myocardial infarction—Dexamethasone—psoriasis	0.000116	0.00338	CcSEcCtD
Drospirenone—Myocardial infarction—Betamethasone—psoriasis	0.000116	0.00338	CcSEcCtD
Drospirenone—PGR—Cellular roles of Anthrax toxin—TNF—psoriasis	0.000116	0.0108	CbGpPWpGaD
Drospirenone—Cerebrovascular accident—Methotrexate—psoriasis	0.000114	0.00333	CcSEcCtD
Drospirenone—PGR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000111	0.0104	CbGpPWpGaD
Drospirenone—Nausea—Acitretin—psoriasis	0.000111	0.00324	CcSEcCtD
Drospirenone—Nausea—Fluocinolone Acetonide—psoriasis	0.000111	0.00323	CcSEcCtD
Drospirenone—Mental disorder—Hydrocortisone—psoriasis	0.000109	0.00318	CcSEcCtD
Drospirenone—AR—Nuclear Receptors—PPARG—psoriasis	0.000107	0.01	CbGpPWpGaD
Drospirenone—Haemoglobin—Betamethasone—psoriasis	0.000107	0.00311	CcSEcCtD
Drospirenone—Haemoglobin—Dexamethasone—psoriasis	0.000107	0.00311	CcSEcCtD
Drospirenone—Haemorrhage—Betamethasone—psoriasis	0.000106	0.0031	CcSEcCtD
Drospirenone—Haemorrhage—Dexamethasone—psoriasis	0.000106	0.0031	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000106	0.00309	CcSEcCtD
Drospirenone—Mood swings—Methotrexate—psoriasis	0.000106	0.00309	CcSEcCtD
Drospirenone—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000105	0.0574	CbGdCrCtD
Drospirenone—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000105	0.0574	CbGdCrCtD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000104	0.00974	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000103	0.003	CcSEcCtD
Drospirenone—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000103	0.0561	CbGdCrCtD
Drospirenone—Depression—Prednisone—psoriasis	0.000103	0.003	CcSEcCtD
Drospirenone—Acute coronary syndrome—Prednisone—psoriasis	0.000101	0.00296	CcSEcCtD
Drospirenone—Myocardial infarction—Prednisone—psoriasis	0.000101	0.00295	CcSEcCtD
Drospirenone—Breast disorder—Methotrexate—psoriasis	0.000101	0.00295	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.0001	0.00293	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	9.78e-05	0.00917	CbGpPWpGaD
Drospirenone—Nervous system disorder—Cyclosporine—psoriasis	9.74e-05	0.00284	CcSEcCtD
Drospirenone—Skin disorder—Cyclosporine—psoriasis	9.64e-05	0.00282	CcSEcCtD
Drospirenone—Angiopathy—Dexamethasone—psoriasis	9.63e-05	0.00281	CcSEcCtD
Drospirenone—Angiopathy—Betamethasone—psoriasis	9.63e-05	0.00281	CcSEcCtD
Drospirenone—Nervous system disorder—Mycophenolate mofetil—psoriasis	9.5e-05	0.00277	CcSEcCtD
Drospirenone—Skin disorder—Mycophenolate mofetil—psoriasis	9.41e-05	0.00275	CcSEcCtD
Drospirenone—Haemoglobin—Prednisone—psoriasis	9.29e-05	0.00271	CcSEcCtD
Drospirenone—Haemorrhage—Prednisone—psoriasis	9.24e-05	0.0027	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.2e-05	0.00863	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	9.14e-05	0.00267	CcSEcCtD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	8.73e-05	0.00819	CbGpPWpGaD
Drospirenone—Nausea—Hydroxyurea—psoriasis	8.7e-05	0.00254	CcSEcCtD
Drospirenone—BCHE—Peptide hormone metabolism—ACE—psoriasis	8.69e-05	0.00815	CbGpPWpGaD
Drospirenone—Nervous system disorder—Hydrocortisone—psoriasis	8.65e-05	0.00253	CcSEcCtD
Drospirenone—Depression—Methotrexate—psoriasis	8.58e-05	0.0025	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Cyclosporine—psoriasis	8.57e-05	0.0025	CcSEcCtD
Drospirenone—Skin disorder—Hydrocortisone—psoriasis	8.57e-05	0.0025	CcSEcCtD
Drospirenone—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	8.47e-05	0.00794	CbGpPWpGaD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	8.41e-05	0.00788	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	8.39e-05	0.00787	CbGpPWpGaD
Drospirenone—Angiopathy—Prednisone—psoriasis	8.38e-05	0.00245	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.36e-05	0.00244	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	8.19e-05	0.00768	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	8.16e-05	0.00765	CbGpPWpGaD
Drospirenone—Mental disorder—Prednisone—psoriasis	8.1e-05	0.00236	CcSEcCtD
Drospirenone—Haemoglobin—Methotrexate—psoriasis	7.76e-05	0.00227	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—IL13—psoriasis	7.72e-05	0.00724	CbGpPWpGaD
Drospirenone—Haemorrhage—Methotrexate—psoriasis	7.72e-05	0.00225	CcSEcCtD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	7.63e-05	0.00715	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.62e-05	0.00222	CcSEcCtD
Drospirenone—NR3C2—Generic Transcription Pathway—CARM1—psoriasis	7.57e-05	0.0071	CbGpPWpGaD
Drospirenone—Nervous system disorder—Betamethasone—psoriasis	7.39e-05	0.00216	CcSEcCtD
Drospirenone—Nervous system disorder—Dexamethasone—psoriasis	7.39e-05	0.00216	CcSEcCtD
Drospirenone—Erythema multiforme—Methotrexate—psoriasis	7.3e-05	0.00213	CcSEcCtD
Drospirenone—Nausea—Mycophenolic acid—psoriasis	7.29e-05	0.00213	CcSEcCtD
Drospirenone—AR—Notch-mediated HES/HEY network—CD4—psoriasis	7.17e-05	0.00672	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—TARS—psoriasis	7.06e-05	0.00662	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	7.04e-05	0.0066	CbGpPWpGaD
Drospirenone—Angiopathy—Methotrexate—psoriasis	7.01e-05	0.00205	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.8e-05	0.00199	CcSEcCtD
Drospirenone—Mental disorder—Methotrexate—psoriasis	6.77e-05	0.00198	CcSEcCtD
Drospirenone—AR—FOXA1 transcription factor network—JUN—psoriasis	6.76e-05	0.00634	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	6.72e-05	0.0063	CbGpPWpGaD
Drospirenone—PTGS2—S1P1 pathway—VEGFA—psoriasis	6.65e-05	0.00623	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	6.58e-05	0.00617	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Betamethasone—psoriasis	6.51e-05	0.0019	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Dexamethasone—psoriasis	6.51e-05	0.0019	CcSEcCtD
Drospirenone—Nervous system disorder—Prednisone—psoriasis	6.44e-05	0.00188	CcSEcCtD
Drospirenone—Skin disorder—Prednisone—psoriasis	6.38e-05	0.00186	CcSEcCtD
Drospirenone—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	6.34e-05	0.0346	CbGdCrCtD
Drospirenone—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	6.34e-05	0.0346	CbGdCrCtD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	6.28e-05	0.00589	CbGpPWpGaD
Drospirenone—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	6.2e-05	0.0338	CbGdCrCtD
Drospirenone—Nausea—Cyclosporine—psoriasis	5.9e-05	0.00172	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—JUN—psoriasis	5.83e-05	0.00546	CbGpPWpGaD
Drospirenone—Nausea—Mycophenolate mofetil—psoriasis	5.75e-05	0.00168	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	5.7e-05	0.00534	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.68e-05	0.00166	CcSEcCtD
Drospirenone—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	5.55e-05	0.0052	CbGpPWpGaD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	5.43e-05	0.00509	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—LEP—psoriasis	5.4e-05	0.00506	CbGpPWpGaD
Drospirenone—Nervous system disorder—Methotrexate—psoriasis	5.38e-05	0.00157	CcSEcCtD
Drospirenone—AR—Gene Expression—TARS—psoriasis	5.38e-05	0.00504	CbGpPWpGaD
Drospirenone—Nausea—Prednisolone—psoriasis	5.37e-05	0.00157	CcSEcCtD
Drospirenone—Skin disorder—Methotrexate—psoriasis	5.33e-05	0.00156	CcSEcCtD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	5.29e-05	0.00496	CbGpPWpGaD
Drospirenone—Nausea—Hydrocortisone—psoriasis	5.24e-05	0.00153	CcSEcCtD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	4.95e-05	0.00464	CbGpPWpGaD
Drospirenone—Nausea—Triamcinolone—psoriasis	4.94e-05	0.00144	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—IL10—psoriasis	4.83e-05	0.00453	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Methotrexate—psoriasis	4.74e-05	0.00138	CcSEcCtD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	4.67e-05	0.00438	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	4.65e-05	0.00436	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—CARM1—psoriasis	4.61e-05	0.00433	CbGpPWpGaD
Drospirenone—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	4.6e-05	0.00431	CbGpPWpGaD
Drospirenone—PTGS2—skeletal joint—psoriasis	4.59e-05	0.268	CbGeAlD
Drospirenone—NR3C2—Generic Transcription Pathway—VDR—psoriasis	4.52e-05	0.00424	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	4.51e-05	0.00423	CbGpPWpGaD
Drospirenone—Nausea—Dexamethasone—psoriasis	4.48e-05	0.00131	CcSEcCtD
Drospirenone—Nausea—Betamethasone—psoriasis	4.48e-05	0.00131	CcSEcCtD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	4.19e-05	0.00393	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	4.15e-05	0.00389	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—TYK2—psoriasis	4.07e-05	0.00381	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	4.06e-05	0.00381	CbGpPWpGaD
Drospirenone—Nausea—Prednisone—psoriasis	3.9e-05	0.00114	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—JUN—psoriasis	3.85e-05	0.00361	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	3.77e-05	0.00354	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.75e-05	0.00352	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	3.69e-05	0.00346	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—CARM1—psoriasis	3.65e-05	0.00342	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.61e-05	0.00339	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—CARM1—psoriasis	3.51e-05	0.0033	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	3.51e-05	0.00329	CbGpPWpGaD
Drospirenone—PTGS2—synovial membrane of synovial joint—psoriasis	3.49e-05	0.203	CbGeAlD
Drospirenone—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	3.39e-05	0.00318	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL4—psoriasis	3.38e-05	0.00317	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—STAT3—psoriasis	3.33e-05	0.00312	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.28e-05	0.00307	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HCAR2—psoriasis	3.27e-05	0.00307	CbGpPWpGaD
Drospirenone—Nausea—Methotrexate—psoriasis	3.26e-05	0.000952	CcSEcCtD
Drospirenone—NR3C2—Generic Transcription Pathway—PPARG—psoriasis	3.15e-05	0.00296	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.15e-05	0.00295	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	3.08e-05	0.00289	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—LEP—psoriasis	2.86e-05	0.00268	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TAGAP—psoriasis	2.83e-05	0.00266	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.81e-05	0.00263	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—VDR—psoriasis	2.75e-05	0.00258	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	2.68e-05	0.00252	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—NOS2—psoriasis	2.66e-05	0.0025	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NDUFA5—psoriasis	2.65e-05	0.00248	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.64e-05	0.00248	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—REN—psoriasis	2.63e-05	0.00247	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	2.63e-05	0.00246	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CD4—psoriasis	2.59e-05	0.00243	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	2.58e-05	0.00242	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	2.52e-05	0.00236	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.47e-05	0.00231	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—JUN—psoriasis	2.46e-05	0.0023	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	2.43e-05	0.00228	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.36e-05	0.00222	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP2S1—psoriasis	2.25e-05	0.00211	CbGpPWpGaD
Drospirenone—PTGS2—skin epidermis—psoriasis	2.24e-05	0.13	CbGeAlD
Drospirenone—PGR—Gene Expression—CARM1—psoriasis	2.22e-05	0.00208	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	2.2e-05	0.00207	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—VDR—psoriasis	2.18e-05	0.00204	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.16e-05	0.00202	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	2.15e-05	0.00202	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.15e-05	0.00201	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—VDR—psoriasis	2.1e-05	0.00197	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.09e-05	0.00196	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IFNG—psoriasis	2.04e-05	0.00192	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.01e-05	0.00189	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—IL6—psoriasis	1.99e-05	0.00186	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—PPARG—psoriasis	1.92e-05	0.0018	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	1.9e-05	0.00178	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—TNF—psoriasis	1.84e-05	0.00172	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.83e-05	0.00171	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NDUFA5—psoriasis	1.82e-05	0.00171	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.81e-05	0.0017	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.7e-05	0.00159	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CCL20—psoriasis	1.7e-05	0.00159	CbGpPWpGaD
Drospirenone—AR—Gene Expression—CARM1—psoriasis	1.69e-05	0.00159	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	1.67e-05	0.00157	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.66e-05	0.00156	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—ACE—psoriasis	1.64e-05	0.00154	CbGpPWpGaD
Drospirenone—PTGS2—endothelium—psoriasis	1.62e-05	0.0947	CbGeAlD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.56e-05	0.00147	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP2S1—psoriasis	1.55e-05	0.00145	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—PPARG—psoriasis	1.52e-05	0.00142	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL6—psoriasis	1.48e-05	0.00139	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—PPARG—psoriasis	1.46e-05	0.00137	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.38e-05	0.00129	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.35e-05	0.00126	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—VDR—psoriasis	1.33e-05	0.00124	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.32e-05	0.00124	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.2e-05	0.00113	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.18e-05	0.00111	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.17e-05	0.00109	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.16e-05	0.00108	CbGpPWpGaD
Drospirenone—NR3C2—tendon—psoriasis	1.14e-05	0.0663	CbGeAlD
Drospirenone—AR—skin of body—psoriasis	1.11e-05	0.0645	CbGeAlD
Drospirenone—BCHE—Metabolism—CARM1—psoriasis	1.1e-05	0.00103	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.07e-05	0.001	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.05e-05	0.000984	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.03e-05	0.000963	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—LEP—psoriasis	1.02e-05	0.000956	CbGpPWpGaD
Drospirenone—AR—Gene Expression—VDR—psoriasis	1.01e-05	0.000947	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SOCS1—psoriasis	9.35e-06	0.000877	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—PPARG—psoriasis	9.25e-06	0.000867	CbGpPWpGaD
Drospirenone—BCHE—skin of body—psoriasis	9e-06	0.0525	CbGeAlD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.99e-06	0.000843	CbGpPWpGaD
Drospirenone—AR—tendon—psoriasis	8.42e-06	0.0491	CbGeAlD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.12e-06	0.000761	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.93e-06	0.000743	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CARM1—psoriasis	7.57e-06	0.000709	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.07e-06	0.000663	CbGpPWpGaD
Drospirenone—AR—Gene Expression—PPARG—psoriasis	7.04e-06	0.00066	CbGpPWpGaD
Drospirenone—PTGS2—skin of body—psoriasis	6.93e-06	0.0404	CbGeAlD
Drospirenone—PGR—Signaling Pathways—LEP—psoriasis	6.9e-06	0.000647	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—APOE—psoriasis	6.9e-06	0.000647	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CXCL8—psoriasis	6.77e-06	0.000635	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CAT—psoriasis	6.76e-06	0.000634	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NFKBIA—psoriasis	6.43e-06	0.000603	CbGpPWpGaD
Drospirenone—PTGS2—tendon—psoriasis	5.28e-06	0.0308	CbGeAlD
Drospirenone—PGR—Signaling Pathways—TYK2—psoriasis	5.27e-06	0.000494	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—APOE—psoriasis	5.25e-06	0.000493	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CAT—psoriasis	4.65e-06	0.000436	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HLA-A—psoriasis	4.62e-06	0.000434	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCL8—psoriasis	4.59e-06	0.00043	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PPARG—psoriasis	4.58e-06	0.000429	CbGpPWpGaD
Drospirenone—PTGS2—Disease—APOE—psoriasis	4.32e-06	0.000405	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—JUN—psoriasis	4.26e-06	0.0004	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NFKB1—psoriasis	4.1e-06	0.000385	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NOS2—psoriasis	4.02e-06	0.000377	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VEGFA—psoriasis	3.72e-06	0.000349	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—STAT3—psoriasis	3.69e-06	0.000346	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—APOE—psoriasis	3.62e-06	0.000339	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TYK2—psoriasis	3.3e-06	0.000309	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PPARG—psoriasis	3.15e-06	0.000295	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CD4—psoriasis	2.98e-06	0.000279	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TP53—psoriasis	2.81e-06	0.000264	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL6—psoriasis	2.58e-06	0.000242	CbGpPWpGaD
Drospirenone—PTGS2—Disease—STAT3—psoriasis	2.31e-06	0.000216	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IL6—psoriasis	1.61e-06	0.000151	CbGpPWpGaD
